New blood pressure drug found lacking

May 10, 2007

A U.S. study has determined the first of a new class of drugs designed to treat hypertension has limited effectiveness.

There are currently seven classes of drugs used to reduce blood pressure. Aliskiren (Tekturna and Rasilez) is the first of a new class of orally active anti-hypertensive drugs that works by inhibiting the enzyme rennin that can raise blood pressure.

But a review of six large-scale clinical trials of aliskiren by Jean Sealey and Dr. John Laragh of the Weill Cornell Medical College found, because of reactive renin secretion, the drug has not been any more effective than those already widely available to control hypertension.

Laragh and Sealey found in analyzing clinical trials involving more than 5,000 hypertensive patients, aliskiren was no more effective as an anti-hypertensive agent than converting enzyme inhibitors, angiotensin receptor blockers or diuretics.

The research is detailed in the May issue of the American Journal of Hypertension.

Copyright 2007 by United Press International

Explore further: FDA approves AbbVie combo hepatitis C treatment

add to favorites email to friend print save as pdf

Related Stories

Baby cells learn to communicate using the lsd1 gene

29 minutes ago

We would not expect a baby to join a team or participate in social situations that require sophisticated communication. Yet, most developmental biologists have assumed that young cells, only recently born ...

People finding their 'waze' to once-hidden streets

14 hours ago

When the people whose houses hug the narrow warren of streets paralleling the busiest urban freeway in America began to see bumper-to-bumper traffic crawling by their homes a year or so ago, they were baffled.

Identity theft victims face months of hassle

14 hours ago

As soon as Mark Kim found out his personal information was compromised in a data breach at Target last year, the 36-year-old tech worker signed up for the retailer's free credit monitoring offer so he would ...

Observers slam 'lackluster' Lima climate deal

14 hours ago

A carbon-curbing deal struck in Lima on Sunday was a watered-down compromise where national intransigence threatened the goal of a pact to save Earth's climate system, green groups said.

Your info has been hacked. Now what do you do?

14 hours ago

Criminals stole personal information from tens of millions of Americans in data breaches this past year. Of those affected, one in three may become victims of identity theft, according to research firm Javelin. ...

Recommended for you

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.